Literature DB >> 16033070

Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.

Udo Jeschke1, Ioannis Mylonas, Naim Shabani, Christiane Kunert-Keil, Christian Schindlbeck, Bernd Gerber, Klaus Friese.   

Abstract

OBJECTIVE: Breast cancer cells can invade and generate metastasis via either lymphatic or blood vessels. Sialyl Lewis X (SLeX) and Sialyl Lewis a (SLea) are carbohydrate molecules that mediate the adhesion between tumor cells and the endothelium. These antigens are not expressed on normal breast tissue. Overexpression of SLeX and SLea is combined with poor prognosis and malignant relapse. E-cadherin mediates tumor cell-tumor cell adhesion. Partial or complete loss of E-cadherin expression has also been found to correlate with poor prognosis in breast cancer patients. Another factor involved in metastasis is Cathepsin-D, a lysosomalprotease. Cathepsin-D plays a role in cell proliferation and inhibition of tumor cell adhesion. In this study, we analysed the combined expression of SLeX, SLea, Cathepsin-D and E-cadherin in breast carcinoma in situ, invasive carcinomas without metastasis and invasive carcinomas with lymph node metastasis.
MATERIALS AND METHODS: Slides of paraffin-embedded tissue of carcinoma in situ (8 DCIS, 2 CLIS), invasive carcinomas without metastasis (9 ductal, 1 lobular) and carcinomas (7 ductal, 2 lobular, 1 mucinous) with their lymph node metastasis (10 cases) were used. Breast cancer tissue was fixed and incubated with monoclonal antibodies against SLex (IgM) and SLea (IgM), Cathepsin-D (IgG) and E-cadherin (IgG). Staining reaction was performed with the ABC reagent. The intensity of immunohistochemical reaction on digital images of the slides was analyzed using a computer-aided detection system.
RESULTS: We found a weak expression of both Sialyl Lewis antigens, a strong expression of E-cadherin and a moderate expression of Cathepsin-D in carcinoma in situ. The expression of both Sialyl Lewis antigens, E-cadherin and Cathepsin-D was moderate in invasive carcinomas without metastases. However, a strong expression of both Sialyl Lewis antigens and a very weak expression of E-cadherin was detected in primary carcinoma with lymph node metastases. The expression of Cathepsin-D was moderate in this tissue. E-cadherin expression was elevated whereas SLeX and Cathepsin-D expression was reduced in lymph node metastases compared to the primary tumor.
CONCLUSION: Combined analysis of tumor antigens involved in adhesion of breast cancer cells showed a negative correlation between Sialyl Lewis antigens and E-cadherin as the risk of metastasis progresses. Furthermore, there were significant differences of expression of the Sialyl Lewis antigens, E-cadherin and Cathepsin-D in primary breast cancer cells and their metastases. Evaluation of a panel of markers involved in cell adhesion could be a useful method for defining the metastatic risk in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033070

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  31 in total

1.  Expression of the blood-group-related antigens Sialyl Lewis a, Sialyl Lewis x and Lewis y in term placentas of normal, preeclampsia, IUGR- and HELLP-complicated pregnancies.

Authors:  Vassilis Minas; Ioannis Mylonas; Barbara Schiessl; Doris Mayr; Sandra Schulze; Klaus Friese; Udo Jeschke; Antonis Makrigiannakis
Journal:  Histochem Cell Biol       Date:  2007-06-06       Impact factor: 4.304

2.  Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

Authors:  Polina Weitzenfeld; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

3.  Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines.

Authors:  Siddarth Chandrasekaran; Yue Geng; Lisa A DeLouise; Michael R King
Journal:  Biomaterials       Date:  2012-09-17       Impact factor: 12.479

4.  Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Authors:  Evan N Cohen; Tamer M Fouad; Bang-Ning Lee; Banu K Arun; Diane Liu; Sanda Tin; Angelica M Gutierrez Barrera; Toshihide Miura; Iwao Kiyokawa; Jun Yamashita; Ricardo H Alvarez; Vicente Valero; Wendy A Woodward; Yu Shen; Naoto T Ueno; Massimo Cristofanilli; James M Reuben
Journal:  Breast Cancer Res Treat       Date:  2019-05-03       Impact factor: 4.872

Review 5.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

6.  High FUT3 expression is a marker of lower overall survival of breast cancer patients.

Authors:  Jessica Catarine Frutuoso do Nascimento; Eduardo Isidoro Carneiro Beltrão; Cíntia Renata Costa Rocha
Journal:  Glycoconj J       Date:  2020-02-15       Impact factor: 2.916

Review 7.  Tumour-associated carbohydrate antigens in breast cancer.

Authors:  Aurélie Cazet; Sylvain Julien; Marie Bobowski; Joy Burchell; Philippe Delannoy
Journal:  Breast Cancer Res       Date:  2010-06-08       Impact factor: 6.466

8.  Modeling the excitation wavelengths (lambda(ex)) of boronic acids.

Authors:  Minyong Li; Nanting Ni; Binghe Wang; Yanqing Zhang
Journal:  J Mol Model       Date:  2008-03-20       Impact factor: 1.810

9.  Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature.

Authors:  Sandra O Demichelis; Marina T Isla-Larrain; Luciano Cermignani; Cecilio G Alberdi; Amada Segal-Eiras; María Virginia Croce
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-12-20

10.  Protein modifications as potential biomarkers in breast cancer.

Authors:  Hongjun Jin; Richard C Zangar
Journal:  Biomark Insights       Date:  2009-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.